Senior investor and executive with operational and investing experience across healthcare and consumer sectors. Tabitha Letourneau Meyerer is known for leading growth-stage investing, portfolio company oversight, and strategic M&A; background includes private equity and corporate development roles, board seats, and hands-on operating leadership. Market-oriented profile: focus on scaling revenue, unit economics, and exit preparation; typically engages in Series B–C rounds and strategic carve-outs.
Senior investor and executive with operational and investing experience across healthcare and consumer sectors. Tabitha Letourneau Meyerer is known for leading growth-stage investing, portfolio company oversight, and strategic M&A; background includes private equity and corporate development roles, board seats, and hands-on operating leadership. Market-oriented profile: focus on scaling revenue, unit economics, and exit preparation; typically engages in Series B–C rounds and strategic carve-outs.
Seasoned growth-stage investor and operator focusing on healthcare and consumer businesses. Prioritizes revenue-scalable models, improving unit economics, and clear pathways to exit. Prefers Series B–C and strategic carve-outs where operational playbooks, disciplined capital allocation, and board-level engagement accelerate value creation. Underwriting emphasizes durable unit margins, repeatable go-to-market, and management quality; time horizon is medium-term (3–7 years) with active governance, milestone-based follow-on capital, and pragmatic M&A-driven liquidity as key levers.
Seasoned growth-stage investor and operator focusing on healthcare and consumer businesses. Prioritizes revenue-scalable models, improving unit economics, and clear pathways to exit. Prefers Series B–C and strategic carve-outs where operational playbooks, disciplined capital allocation, and board-level engagement accelerate value creation. Underwriting emphasizes durable unit margins, repeatable go-to-market, and management quality; time horizon is medium-term (3–7 years) with active governance, milestone-based follow-on capital, and pragmatic M&A-driven liquidity as key levers.
| Trades 1634 | Longs Won 1024/1634 62% | Profit Factor 9.57 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.31M |
| Average Win $165,831.74 | Best Trade (Jul 30) $51.22M | Sharpe Ratio -9.26 |
| Average Loss -$29,076 | Worst Trade (Mar 31) -$1.4M | Z-Score -6.09 (100%) |
| Commissions $0 | Avg. Trade Length 8m 4d | Expectancy $93,069.36 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% | 0.95% |
| Consecutive Losing Trades | 14,085 | 12,676 | 11,268 | 9,859 | 8,451 | 7,042 | 5,634 | 4,225 | 2,817 | 1,408 |